Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis

Filippini, Graziella; Borrelli, Francesca; Cinquini, Michela; Dwan, Kerry

doi:10.1002/14651858.cd013444.pub2

Cited by 36 publications

(32 citation statements)

References 140 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cannabis may be used to treat different symptoms of MS, as spasticity and fatigue (Filippini et al, 2019;Nielsen et al, 2018). It modulates cholinergic, GABAergic, serotonergic, beta-adrenergic, and cannabinoid systems, suggesting possible therapeutic effects on tremor (Makhoul et al, 2020).…”

Section: Cannabis-based Medicinementioning

confidence: 99%

Pharmacological treatment of tremor in multiple sclerosis; a systematic review

Pourmohammadi

Riahi

Hosseini

et al. 2022

Multiple Sclerosis and Related Disorders

View full text Add to dashboard Cite

Section: Cannabis-based Medicinementioning

confidence: 99%

Pharmacological treatment of tremor in multiple sclerosis; a systematic review

Pourmohammadi

Riahi

Hosseini

et al. 2022

Multiple Sclerosis and Related Disorders

View full text Add to dashboard Cite

“…Half to two-thirds of MS patients under nabiximols report spasticity relief within 4 weeks, and 40% of patients will reach at least 30% subjective improvement at 3 months, including most patients under long-term treatment [35 ▪ ]. A recent Cochrane review concluded that, compared with placebo, nabiximols probably reduces the severity of MS-related spasticity in the short-term, but the effect on chronic pain, health-related QoL, and drug tolerance are uncertain [37 ▪ ]. A real-world evidence study of nabiximols in MS patients with resistant spasticity showed beneficial effect on spasticity-plus syndrome, that is, spasticity associated with pain, sleep disturbances, and spasm/cramp [38].…”

Section: Treatment Of Spasticitymentioning

confidence: 99%

Spasticity following brain and spinal cord injury: assessment and treatment

Tamburin

Filippetti

Mantovani

et al. 2022

Current Opinion in Neurology

View full text Add to dashboard Cite

Purpose of reviewSpasticity is a common sequela of brain and spinal cord injury and contributes to disability, reduces quality of life, and increases economic burden. Spasticity is still incompletely recognized and undertreated. We will provide an overview of recent published data on the definition, assessment, and prediction, therapeutic advances, with a focus on promising new approaches, and telemedicine applications for spasticity.Recent findingsTwo new definitions of spasticity have been recently proposed, but operational criteria should be developed, and test–retest and inter-rater reliability should be explored. Cannabinoids proved to be effective in spasticity in multiple sclerosis, but evidence in other types of spasticity is lacking. Botulinum neurotoxin injection is the first-line therapy for focal spasticity, and recent literature focused on optimizing its efficacy. Several pharmacological, interventional, and nonpharmacological therapeutic approaches for spasticity have been explored but low-quality evidence impedes solid conclusions on their efficacy. The recent COVID-19 pandemic yielded guidelines/recommendations for the use of telemedicine in spasticity.SummaryDespite the frequency of spasticity, robust diagnostic criteria and reliable assessment scales are required. High-quality studies are needed to support the efficacy of current treatments for spasticity. Future studies should explore telemedicine tools for spasticity assessment and treatment.

show abstract

“…In the context of brain disorders, CBD has shown anticonvulsant, anxiolytic, antipsychotic and antidepressant effects in animal models and human studies [ 10 , 15 , 16 , 17 , 18 ]. The diverse pharmacological profile of CBD has attracted considerable attention worldwide, and many clinical trials have been designed to evaluate its therapeutic properties [ 19 , 20 , 21 , 22 ]. Currently, CBD is approved by the US Food and Drug Administration (FDA, Silver Spring, MD, USA) and European Medicines Agency (EMA, Amsterdam, The Netherlands) as an add-on treatment for rare epilepsies, and a preparation of 1:1 CBD+THC is approved in several European countries and Canada for the treatment of multiple-sclerosis-associated spasticity [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

Regulation of DNA Methylation by Cannabidiol and Its Implications for Psychiatry: New Insights from In Vivo and In Silico Models

Domingos

Silva

Filho

et al. 2022

Genes

View full text Add to dashboard Cite

Cannabidiol (CBD) is a non-psychotomimetic compound present in cannabis sativa. Many recent studies have indicated that CBD has a promising therapeutic profile for stress-related psychiatric disorders, such as anxiety, schizophrenia and depression. Such a diverse profile has been associated with its complex pharmacology, since CBD can target different neurotransmitter receptors, enzymes, transporters and ion channels. However, the precise contribution of each of those mechanisms for CBD effects is still not yet completely understood. Considering that epigenetic changes make the bridge between gene expression and environment interactions, we review and discuss herein how CBD affects one of the main epigenetic mechanisms associated with the development of stress-related psychiatric disorders: DNA methylation (DNAm). Evidence from in vivo and in silico studies indicate that CBD can regulate the activity of the enzymes responsible for DNAm, due to directly binding to the enzymes and/or by indirectly regulating their activities as a consequence of neurotransmitter-mediated signaling. The implications of this new potential pharmacological target for CBD are discussed in light of its therapeutic and neurodevelopmental effects.

show abstract

Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis

Cited by 36 publications

References 140 publications

Pharmacological treatment of tremor in multiple sclerosis; a systematic review

Pharmacological treatment of tremor in multiple sclerosis; a systematic review

Spasticity following brain and spinal cord injury: assessment and treatment

Regulation of DNA Methylation by Cannabidiol and Its Implications for Psychiatry: New Insights from In Vivo and In Silico Models

Contact Info

Product

Resources

About